Search Results
Aug 04, 2026, 06:52 ET Detrás de cada respiro hay una historia: El Día Mundial de las NTM 2026 pone en primer plano una enfermedad pulmonar poco reconocida
https://www.multivu.com/ntm-info-and-research/9410751-es-world-ntm-day-2026-spotlights-lung-disease La enfermedad pulmonar por micobacterias no tuberculosas, o NTM, es causada por bacterias que
More news about: NTM Info & Research (NTMir)
Aug 04, 2026, 06:00 ET IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
trial (neoadjuvant primary UM) to be presented at ESMOUpdated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO Announced clinical collaboration with Roche to evaluate
More news about: IDEAYA Biosciences, Inc.
Aug 04, 2026, 05:00 ET MemorialCare Hospitals Recognized by U.S. News & World Report's 2026-2027 Best Hospitals in 38 High-Performing Rankings, One National in OB GYN
Disease (COPD), Diabetes, Heart Arrhythmia, Heart Attack, Heart Failure, Hip Fracture, Kidney Failure, Knee Replacement, Leukemia, Lymphoma & Myeloma, Lung Cancer Surgery, Pacemaker Implantation, Pneumonia and Stroke.Orange Coast Medical Center earned High Performing ratings in 14 adult procedures
More news about: MemorialCare
Aug 04, 2026, 05:00 ET NYU Langone Health Once Again Holds the Most No. 1-Ranked Specialties in the Nation in 'U.S. News & World Report' Rankings
cardiology, heart, and vascular surgery (second year in a row)No. 2 in geriatricsNo. 2 in orthopedicsNo. 2 in pulmonology and lung surgeryNo. 2 in urologyNo. 4 in diabetes and endocrinologyNo. 6 in gastroenterology and GI surgeryNo. 6 in rehabilitation,
More news about: NYU Langone Health System
Aug 04, 2026, 01:58 ET 美國 FDA 授予再鼎醫藥靶向 DLL3 抗體藥物偶聯物 Zocilurtatug Pelitecan（Zoci）孤兒藥資格認定，用於治療神經內分泌癌（NEC）
參考文獻：[1] J Thorac Oncol. 2023 Jan:18(1):31-46; Lung Cancer Foundation of America[2]
More news about: 再鼎醫藥
Aug 03, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 29, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762
More news about: TransMedics Group, Inc.
Aug 03, 2026, 10:30 ET Tumor Ablation Market worth $1.89 billion by 2031 - Exclusive Report by MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258The tumor ablation market is experiencing significant growth because of the high prevalence rate of cancers globally, especially liver, lung, renal, bone, and prostate cancers, which have been found to be successfully treated using ablation therapy. The rapid trend toward minimally invasive
More news about: MarketsandMarkets
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,8 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 11,3 Tỷ USD
liên kết tại đây) cho tháng 7 năm 2026. Tiêu đề của Thông Điệp này là "ETH chính là liều thuốc giải cho Thung Lũng Kỳ Lạ của Sự Giàu Có."Vào đầu năm 2026, Bitmine đã ra mắt MAVAN (Made in American VAlidator Network) — nền tảng staking chuyên biệt dành cho
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:00 ET Cizzle Bio Expands Access to Early Lung Cancer Detection Through Strategic Laboratory Collaboration with BioBridge Global in South Texas
high-impact, minimally invasive biomarker blood test in regions facing a significant lung cancer burden and health disparities."Early detection can dramatically improve outcomes, yet too many patients are diagnosed after lung cancer has progressed," said Bill Behnke, founder and CEO of Cizzle Bio. "Our
More news about: Cizzle Bio
Aug 03, 2026, 07:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression ≥ 50%, as determined by FDA approved tests.
More news about: Eli Lilly and Company
Aug 03, 2026, 07:00 ET Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
More news about: Genprex, Inc.
Aug 03, 2026, 04:59 ET Invenio Imaging Announces Completion of Enrollment in Landmark Study of AI-Based Image Analysis for Lung Cancer
study of this scope and importance."NIO® Lung Cancer Reveal received FDA Breakthrough Device Designation for its intended use to assist physicians in the evaluation of bronchoscopic lung forceps biopsies. The NIO® Lung Cancer Reveal detects cell/tissue morphology suspicious
More news about: Invenio Imaging
Aug 01, 2026, 15:16 ET resbiotic® vuelve a casa, a Texas: La marca microbioma con sede en Dallas llega en H-E-B
fundada por médicos y con sede central en Dallas, Texas, anunció el lanzamiento de dos de sus fórmulas respaldadas por la ciencia —el probiótico resB® Lung Support y el prebiótico resG prebeet®— en las tiendas H-E-B de todo Texas.
More news about: Resbiotic Nutrition, Inc.
Jul 31, 2026, 14:03 ET resbiotic® Comes Home to Texas: Dallas-Based Microbiome Brand Launches at H-E-B
Physician-founded, Texas-headquartered microbiome brand brings flagship Gut-Lung Axis probiotic resB® and daily prebiotic resG prebeet® to H-E-B shelves statewide. DALLAS, July 31, 2026 /PRNewswire/ -- Today,
More news about: Resbiotic Nutrition, Inc.
Jul 31, 2026, 10:00 ET Cincinnati Children's Receives $38.4 Million NIH Grant Renewal to Expand Landmark Congenital Heart Disease Genomics Program
July 31, 2026 /PRNewswire/ -- Cincinnati Children's has received a six-year, $38.4 million grant renewal from the National Heart, Lung, and Blood Institute to continue coordinating a national research program aimed at improving understanding and care for children and adults born with
More news about: Cincinnati Children's Hospital Medical Center
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
inhibitor–based ADC and T‑cell engager platforms within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer (SCLC), platinum-resistant ovarian cancer (PROC) and multiple myeloma (MM).At the European Hematology Association
More news about: AbbVie
Jul 30, 2026, 22:08 ET Iron Software Backs People Over Robots in Fight Against Ocean Plastic
less tech, more people."The Bang Kachao ProjectBang Kachao is a peninsula in the Chao Phraya River, often called Bangkok's "green lung." Unlike the developed concrete banks elsewhere along the river, Bang Kachao remains predominantly mangrove and forest across its six sub-districts.
More news about: Iron Software
Jul 30, 2026, 08:30 ET Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
If an anaphylactic reaction occurs, permanently discontinue RYBREVANT.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO and RYBREVANT can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO with LAZCLUZE
More news about: Johnson & Johnson
Jul 30, 2026, 06:50 ET Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billionAdvanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrenceAnnounced
More news about: Labcorp Holdings Inc
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as non-small cell lung cancer (NSCLC), breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique,
More news about: Kelun-Biotech
Jul 30, 2026, 04:46 ET LUNGevity Foundation Named a Charity for the 2027 Double TCS London Marathon
to be diagnosed and live with lung cancer. While many organizations focus on one aspect of lung cancer, LUNGevity works across research, advocacy, and patient support, because lasting progress requires connecting all three.As the largest nonprofit funder of lung cancer research in the United States,
More news about: LUNGevity Foundation
Jul 29, 2026, 10:01 ET Biopsy Devices Market to Reach US$ 11.2 Bn by 2033 Advances with AI-Driven Precision Diagnostics - Persistence Market Research
projected to increase by 77% between 2022 and 2050, placing greater pressure on hospitals and diagnostic centers to expand biopsy capabilities. Breast, lung, prostate, colorectal, and liver cancers continue to account for a large proportion of biopsy procedures globally.Access Free Sample Now:
More news about: Persistence Market Research Pvt. Ltd.
Jul 29, 2026, 09:00 ET 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
closer to routine clinical care."The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better
More news about: 10x Genomics, Inc.
Jul 29, 2026, 08:25 ET IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Jul 29, 2026, 08:00 ET New HOPE Initiative in Oklahoma Aims to Get At-Risk Residents Screened for Lung Cancer
average of 18.2%.While anyone with lungs can get lung cancer, smoking is the number one risk factor, causing approximately 80% of lung cancer cases."Lung cancer screening detects lung cancer early and can save lives. If lung cancer is caught at an early stage, the likelihood of surviving
More news about: American Lung Association